Larimar Therapeutics’ Friedreich’s ataxia program is free at last, with the FDA fully lifting a clinical hold that had remained in part on the program since 2021. The rare disease biotech can now ...
The Dominican Republic wants jewelers to love larimar, the national stone. But authorities shut the mine temporarily after two fatal accidents. The inspiration for Joarla Caridad’s Pool Ring with ...
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product ...
BALA CYNWYD, Pa., Sept. 28, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare ...
Larimar Therapeutics saw its shares nearly halved in after-hours trading last night after it was hit with an FDA trial hold and had to cancel a planned private raise. The clinical hold is for its ...
Larimar Therapeutics is deeply undervalued, trading at ~$3.40 despite a de-risked safety profile and a clear regulatory path for its lead asset. Nomlabofusp directly addresses Friedreich’s Ataxia’s ...
Hosted on MSN
Larimar Therapeutics Advances Friedreich’s Ataxia Program with New Publications on Nomlabofusp Data
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has announced the publication of two new peer-reviewed articles detailing nonclinical data supporting the therapeutic potential of its ...
Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg ...
Baird analyst Joel Beatty lowered the firm’s price target on Larimar Therapeutics (LRMR) to $7 from $10 and keeps an Outperform rating on the shares. The firm updated its model to reflect increased ...
The latest price target for Larimar Therapeutics (NASDAQ:LRMR) was reported by Oppenheimer on October 2, 2025. The analyst firm set a price target for $21.00 expecting LRMR to rise to within 12 months ...
Detailed price information for Larimar Therapeutics Inc (LRMR-Q) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results